MYOHEART™ (Myogenesis Heart Efficiency and Regeneration Trial)
NCT ID: NCT00054678
Last Updated: 2007-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
20 participants
INTERVENTIONAL
2003-02-28
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The MyoCell™ implantation using the MyoCath™ delivery catheter system may have the potential to add a new dimension to the management of post-infarct deterioration of cardiac function in subjects with congestive heart failure. MyoCath™ is Bioheart's proprietary catheter delivery system being developed by Bioheart to facilitate MyoCell™ delivery into the myocardium via the retrograde catheterization of the left ventricular cavity. Based on pre-clinical studies, implantation of autologous skeletal myoblasts may lead to replacement of non-functioning myocardial scar with functioning muscle and improvement in myocardial performance. Preliminary data in human subjects suggest skeletal myoblast implantation at the time of CABG or via the endoventricular approach may lead to the same effects. In principle, myoblast implantation by catheter delivery may offer the same therapeutic benefit.
The present clinical study is to be conducted primarily to:
1. Assess the safety and effect on myocardial function of MyoCell™ (autologous skeletal myoblast) using a dose escalation methodology following implantation into myocardial scar tissue of subjects with congestive heart failure who have experienced previous myocardial infarction(s) and have had an implantable cardioverter defibrillator (ICD) previously implanted. Safety endpoints will be the evaluation of the nature and frequency of Adverse Events during the 12-month period following MyoCell™ treatment.
2. To assess the safety and feasibility of using the transendocardial injection catheter (MyoCath™) as a system for delivering MyoCell™ into myocardial scar tissue of subjects with congestive heart failure who have experienced previous myocardial infarction(s) and have an implantable cardioverter defibrillator (ICD) previously implanted. Catheter performance will be assessed at the time of the implantation using clinical evaluation questionnaires. Safety endpoints will be the evaluation of the nature and frequency of Adverse Events from the time of implantation to the Day 14 follow-up visit.
If a patient meets the baseline enrollment criteria, approximately 5-10 grams of skeletal muscle is obtained from the subject's leg muscle for myoblast isolation and expansion in vitro (MyoCell™) at a specified off site cGMP culture laboratory. The expanded myoblast cells, MyoCell™ will be implanted into the akinetic myocardial scar in the region of a previous infarct utilizing Bioheart's MyoCath™ transendocardial delivery catheter system. The MyoCath™ endoventricular device is expected to deliver the MyoCell™ autologous skeletal myoblast cells into the scarred myocardial region by steering a catheter which contains a retractable hypodermic needle to the targeted sites for implantation.
This will be a dose escalation study with 4 cohort groups consisting of 5 patients each. A report of the 1 month safety data from each cohort will be presented to the Data Safety Monitoring Board for permission to go to the next higher dosage. In the first cohort of this dose escalation study, 2 injections will be performed; for the second cohort, 6 injections; for the third cohort, 18 injections; and for the fourth cohort, 27 injections, depending on the size of the infarct scar, so as to inject the entire myocardial infarct scar akinetic area.
The entire study is expected to be completed during the first half of 2007, including completed enrollment as well as 12-month follow-up of the last subject.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MyoCell™
MyoCath™
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who have had prior placement of an Implantable Cardioverter Defibrillator (ICD) which must be in place at least one month (30 days) prior to MyoCell™ implantation
* New York Heart Association (NYHA) Symptom Class II or III on optimal medical therapy
* Age \> 30 and \< 80 years old
* Need for revascularization has been ruled out by coronary angiogram or noninvasive stress testing within six months (180 days) of screening
* Able to undergo surgical biopsy of the skeletal muscle and successful culture of the harvested myoblasts Target region wall thickness \> 6 mm by Echocardiography
* Left ventricular ejection fraction \> 20% and \< 40% by Radionuclide Ventriculography or Left Ventricular Angiography at screening
* Able to give written informed consent
* Able to walk a minimum distance of 300 meters during the 6-minute walk test
Exclusion Criteria
* New York Heart Association Symptom Class I or IV
* Coronary Artery Bypass Grafting (CABG) within 3 months (90 days) prior to scheduled MyoCell™ implantation
* Percutaneous Coronary Intervention (PCI) within 6 months (180 days) prior to MyoCell™ implantation
* Canadian Heart Classification of angina \> Class II or unstable angina
* Any cardiac valve replacement
* Heart failure secondary to valvular disease
* Aortic stenosis greater than mild degree
* Left ventricular or atrial mural thrombus
* Chronic pulmonary disease
* Atherosclerosis and/or tortuosity of the aorta, iliac or femoral arteries of a degree which, in the judgment of the principal investigator, would impede or preclude the safe retrograde passage of the 8FR MyoCath™ delivery catheter
* History of severe radiocontrast reaction
* Known sensitivity to gentamicin sulfate and/or amphotericin-B
* Previous angiogenic therapy and/or myocardial laser therapy
* Exposure to any investigational drug or procedure within 1 month prior to study entry
* The use or expected use of antineoplastic drugs or history of cancer within 5 years, except for basal cell carcinoma of the skin
* Skeletal muscle disease, either primary (i.e., myopathy) or secondary (i.e., ischemic) or any underlying myopathy such as myasthenia gravis, muscular dystrophy, etc. as determined by a board certified pathologist examining sample of patients muscle biopsy
* Serum creatinine \> 2.5 mg/dL or end stage renal disease
* Prostate Specific Antigen (PSA) suggestive of carcinoma of the prostate (i.e., \> 4.0 ng/mL)
* Carcinoembryonic Antigen (CEA) \>5.0 ng/mL or end stage renal disease
* Active infectious disease and/or who are known to have tested positive for HIV, HTLV, HBV-sAg, HCV, CMV and/or syphilis. If the panel includes antibodies to the HBc and HBV-sAg, then an expert will be consulted as to patient eligibility based on the patient's infectious status
* Females who are pregnant or nursing
* Females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study
* Morbid obesity - more than 100 pounds over ideal body weight or Body Mass Index (BMI) \> 40
* Any illness which might affect patient's survival over the study 12 month follow-up period\*
* Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
* No written Informed Consent or unable to provide informed consent
30 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bioheart, Inc.
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Warren Sherman, MD
Role: PRINCIPAL_INVESTIGATOR
Columbia University
Timothy Henry, MD
Role: PRINCIPAL_INVESTIGATOR
Minneapolis Heart / Abbott Northwestern
Nicolas Chronos, MD
Role: PRINCIPAL_INVESTIGATOR
St. Joseph Hospital / ACRI
Steven Elliss, MD
Role: PRINCIPAL_INVESTIGATOR
The Cleveland Clinic
David Holmes, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SPONSOR: Bioheart, Inc
Sunrise, Florida, United States
American CardioVascular Research Institute
Atlanta, Georgia, United States
Minneapolis Heart Institute / Abbot Northwestern
Minneapolis, Minnesota, United States
Mayo Clinic Rochester
Rochester, Minnesota, United States
Cleveland Clinic Heart Center
Cleveland, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Bioheart, Incorporated website
American Heart Association
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Version G
Identifier Type: -
Identifier Source: secondary_id
BMI-US-01-002
Identifier Type: -
Identifier Source: org_study_id